Ole Dierks, MD
Nephrology · Oakland, CANPI 1740221514
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Novo Nordisk at 28.7% of the total. 2025 is the largest year on record at $282, 2.8 times the $99 reported in 2019. That places this record below the midpoint for nephrology clinicians in CA, where the typical reported total is $1,018.
Across 29 payments — averaging $24.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$201
- Amgen$123
- Otsuka America Pharmaceutical, Inc.$100
- E.r. Squibb & Sons, L.L.C.$99
- Mallinckrodt Hospital Products Inc.$35
- Apellis Pharmaceuticals, Inc.$27
- plus $118 from 6 others
What the payments were for
- Food & beverage$703100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 11 | $201 |
| Amgen(2 entities) | 5 | $123 |
| Otsuka America Pharmaceutical, Inc. | 4 | $100 |
| E.r. Squibb & Sons, L.L.C. | 1 | $99 |
| Mallinckrodt Hospital Products Inc. | 1 | $35 |
| Apellis Pharmaceuticals, Inc. | 1 | $27 |
| GSK | 1 | $24 |
| Bayer | 1 | $21 |
| Travere Therapeutics, Inc. | 1 | $21 |
| Fresenius USA Marketing, Inc. | 1 | $20 |
| AstraZeneca | 1 | $18 |
| Calliditas Therapeutics US Inc. | 1 | $15 |
How this compares
$703 in reported general payments places this provider in the 40th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 112 | $167,430 |
| Lanthanum Carbonate | 28 | $14,027 |
| ProcritEpoetin Alfa | 12 | $12,600 |
| Sevelamer Carbonate | 31 | $4,556 |
| Bumetanide | 28 | $1,173 |
| Hydralazine Hcl | 79 | $967 |
| Allopurinol | 72 | $675 |
| Losartan Potassium | 71 | $626 |
| Torsemide | 38 | $620 |
| Amlodipine Besylate | 108 | $595 |
| Carvedilol | 45 | $579 |
| Metoprolol Succinate | 53 | $522 |
| Clonidine Hcl | 28 | $396 |
| Lisinopril | 48 | $392 |
| Chlorthalidone | 14 | $345 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Oakland
- Hussain GilaniOakland$118K
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.